NO963728L - Fibroplastvekstfaktor-10 - Google Patents
Fibroplastvekstfaktor-10Info
- Publication number
- NO963728L NO963728L NO963728A NO963728A NO963728L NO 963728 L NO963728 L NO 963728L NO 963728 A NO963728 A NO 963728A NO 963728 A NO963728 A NO 963728A NO 963728 L NO963728 L NO 963728L
- Authority
- NO
- Norway
- Prior art keywords
- disclosed
- polypeptides
- fgf
- polypeptide
- methods
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 abstract 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 102000057243 human FGF10 Human genes 0.000 abstract 1
- 210000003644 lens cell Anatomy 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 230000000250 revascularization Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Humane FGF-10-polypeptider og DNA (RNA) som koder for slike FGF-10-polypeptider er beskrevet. Det er også tilveiebragt en fremgangsmåte for å fremstille et slikt polypeptid ved rekom- binante teknikker. Det er også angitt metoder for å anvende slikt polypeptid for å stimulere revaskularisering, for å behandle sår og hindre neuronal skade. Antagonister mot slike polypeptider og deres anvendelse som et terapeutika for å forhindre unormal celleproliferasjon, hypervaskulære sykdommer og epitel-linsecelleproliferasjon er også omtalt. Diagnostiske metoder for å detektere mutasjoner i FGF-10-kodesekvensen og forandringer i konsentrasjonen av FGF-10-protein i en prøve utledet fra en vert er også angitt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/207,412 US5817485A (en) | 1994-03-08 | 1994-03-08 | Nucleic acids and cells for recombinant production of fibroblast growth factor-10 |
| PCT/US1995/002950 WO1995024414A1 (en) | 1994-03-08 | 1995-03-08 | Fibroblast growth factor-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO963728D0 NO963728D0 (no) | 1996-09-06 |
| NO963728L true NO963728L (no) | 1996-11-07 |
Family
ID=22770445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO963728A NO963728L (no) | 1994-03-08 | 1996-09-06 | Fibroplastvekstfaktor-10 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5817485A (no) |
| EP (2) | EP0750628B1 (no) |
| JP (2) | JPH09510103A (no) |
| CN (1) | CN1150804A (no) |
| AT (1) | ATE251637T1 (no) |
| AU (1) | AU1986195A (no) |
| CA (1) | CA2183961A1 (no) |
| CZ (1) | CZ260696A3 (no) |
| DE (1) | DE69531892T2 (no) |
| DK (1) | DK0750628T3 (no) |
| ES (1) | ES2208676T3 (no) |
| FI (1) | FI963475A (no) |
| HU (1) | HUT77578A (no) |
| IL (1) | IL112878A0 (no) |
| MX (1) | MX9603897A (no) |
| NO (1) | NO963728L (no) |
| PL (1) | PL316202A1 (no) |
| PT (1) | PT750628E (no) |
| SK (1) | SK112996A3 (no) |
| WO (1) | WO1995024414A1 (no) |
| ZA (1) | ZA951886B (no) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
| US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
| US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
| US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| ATE309360T1 (de) | 1994-03-08 | 2005-11-15 | Human Genome Sciences Inc | Vaskularer endothelialer wachstumsfaktor 2 |
| US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US5693775A (en) * | 1995-05-12 | 1997-12-02 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use |
| US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
| JPH11506919A (ja) * | 1995-06-05 | 1999-06-22 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 繊維芽細胞増殖因子１５ |
| US6020189A (en) * | 1996-08-30 | 2000-02-01 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factors (FHFs) and methods of use |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| JPH10279501A (ja) * | 1997-02-10 | 1998-10-20 | Rohto Pharmaceut Co Ltd | 育毛剤 |
| US6335317B1 (en) * | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| WO2000071152A1 (en) * | 1999-05-21 | 2000-11-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 10 |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| JP2004505619A (ja) | 2000-08-04 | 2004-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| US20060183712A1 (en) * | 2005-02-17 | 2006-08-17 | The Texas A&M University System | Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| KR101187871B1 (ko) | 2009-09-23 | 2012-10-05 | (주)케어젠 | Ｆｇｆ１０－유래 펩타이드 및 그의 용도 |
| JP2013544361A (ja) * | 2010-11-23 | 2013-12-12 | ケーシーアイ ライセンシング インク | バイオマーカーを用いた創傷の診断及び治療用の装置及び方法 |
| CN103169658A (zh) * | 2012-10-26 | 2013-06-26 | 温州医学院 | 成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用 |
| EP4183796A1 (en) | 2021-11-19 | 2023-05-24 | Enantis s.r.o. | Thermostable fgf10 polypeptide or fragment thereof use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155214A (en) * | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
| US4868113A (en) * | 1986-03-03 | 1989-09-19 | Rorer Biotechnology, Inc. | Recombinant DNA vector encoding human endothelial cell growth factor |
| JP3303211B2 (ja) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | ｂＦＧＦムテインおよびその製造法 |
| WO1994003199A1 (en) * | 1992-08-04 | 1994-02-17 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
-
1994
- 1994-03-08 US US08/207,412 patent/US5817485A/en not_active Expired - Fee Related
-
1995
- 1995-03-03 IL IL11287895A patent/IL112878A0/xx unknown
- 1995-03-07 ZA ZA951886A patent/ZA951886B/xx unknown
- 1995-03-08 CZ CZ962606A patent/CZ260696A3/cs unknown
- 1995-03-08 ES ES95912829T patent/ES2208676T3/es not_active Expired - Lifetime
- 1995-03-08 EP EP95912829A patent/EP0750628B1/en not_active Expired - Lifetime
- 1995-03-08 EP EP03022286A patent/EP1380594A1/en not_active Withdrawn
- 1995-03-08 AT AT95912829T patent/ATE251637T1/de not_active IP Right Cessation
- 1995-03-08 DE DE69531892T patent/DE69531892T2/de not_active Expired - Fee Related
- 1995-03-08 DK DK95912829T patent/DK0750628T3/da active
- 1995-03-08 MX MX9603897A patent/MX9603897A/es unknown
- 1995-03-08 JP JP7523645A patent/JPH09510103A/ja not_active Ceased
- 1995-03-08 PT PT95912829T patent/PT750628E/pt unknown
- 1995-03-08 CA CA002183961A patent/CA2183961A1/en not_active Abandoned
- 1995-03-08 SK SK1129-96A patent/SK112996A3/sk unknown
- 1995-03-08 CN CN95192340A patent/CN1150804A/zh active Pending
- 1995-03-08 AU AU19861/95A patent/AU1986195A/en not_active Abandoned
- 1995-03-08 HU HU9602434A patent/HUT77578A/hu unknown
- 1995-03-08 PL PL95316202A patent/PL316202A1/xx unknown
- 1995-03-08 WO PCT/US1995/002950 patent/WO1995024414A1/en active IP Right Grant
-
1996
- 1996-09-05 FI FI963475A patent/FI963475A/fi not_active Application Discontinuation
- 1996-09-06 NO NO963728A patent/NO963728L/no unknown
-
2001
- 2001-07-12 US US09/902,773 patent/US20020034787A1/en not_active Abandoned
-
2002
- 2002-03-05 JP JP2002058893A patent/JP2002335982A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE251637T1 (de) | 2003-10-15 |
| AU1986195A (en) | 1995-09-25 |
| NO963728D0 (no) | 1996-09-06 |
| DK0750628T3 (da) | 2004-02-02 |
| EP0750628A1 (en) | 1997-01-02 |
| DE69531892T2 (de) | 2004-07-22 |
| EP0750628B1 (en) | 2003-10-08 |
| WO1995024414A1 (en) | 1995-09-14 |
| US20020034787A1 (en) | 2002-03-21 |
| SK112996A3 (en) | 1997-01-08 |
| MX9603897A (es) | 1997-07-31 |
| JP2002335982A (ja) | 2002-11-26 |
| CA2183961A1 (en) | 1995-09-14 |
| FI963475A0 (fi) | 1996-09-05 |
| FI963475A (fi) | 1996-11-05 |
| JPH09510103A (ja) | 1997-10-14 |
| EP0750628A4 (en) | 1997-06-11 |
| PT750628E (pt) | 2004-03-31 |
| DE69531892D1 (de) | 2003-11-13 |
| HUT77578A (hu) | 1998-06-29 |
| CZ260696A3 (en) | 1997-05-14 |
| US5817485A (en) | 1998-10-06 |
| EP1380594A1 (en) | 2004-01-14 |
| PL316202A1 (en) | 1996-12-23 |
| IL112878A0 (en) | 1995-06-29 |
| HU9602434D0 (en) | 1996-11-28 |
| ZA951886B (en) | 1996-09-09 |
| ES2208676T3 (es) | 2004-06-16 |
| CN1150804A (zh) | 1997-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO963728L (no) | Fibroplastvekstfaktor-10 | |
| DE69636752D1 (de) | Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen | |
| DE69735375D1 (de) | Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung | |
| ATE241639T1 (de) | Keratinozyten-wachstumsfaktor 2 | |
| DE68923107D1 (de) | DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI. | |
| FI863626A (fi) | Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin. | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
| EP0808899A3 (en) | Human marco scavenger receptor (HMarcoSR) | |
| MX9708493A (es) | Factor 15 de crecimiento de fibroblastos. | |
| MX9706854A (es) | Factor 14 de crecimiento de fibroblastos. | |
| MX9709217A (es) | Factor de crecimiento 13 de fibroblastos. | |
| MX9707897A (es) | Factor-11 del crecimiento de fibroblastos. | |
| MX9706204A (es) | Factor 2 de crecimiento de queratinocitos. | |
| MX9709570A (es) | Factor de crecimiento 3 endotelial, vascular, humano. |